JP2019511243A - インビボのデュアルリコンビナーゼ媒介性カセット交換（ｄＲＭＣＥ）のためのシステム及び方法ならびにその疾患モデル - Google Patents

インビボのデュアルリコンビナーゼ媒介性カセット交換（ｄＲＭＣＥ）のためのシステム及び方法ならびにその疾患モデル Download PDF

Info

Publication number
JP2019511243A
JP2019511243A JP2018557283A JP2018557283A JP2019511243A JP 2019511243 A JP2019511243 A JP 2019511243A JP 2018557283 A JP2018557283 A JP 2018557283A JP 2018557283 A JP2018557283 A JP 2018557283A JP 2019511243 A JP2019511243 A JP 2019511243A
Authority
JP
Japan
Prior art keywords
cells
rna
recombinase
transgene
various embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018557283A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019511243A5 (enExample
Inventor
ジョシュア ブレウニグ
ジョシュア ブレウニグ
モーセ ダニエルパー
モーセ ダニエルパー
ジ バム キム
ジ バム キム
Original Assignee
シーダーズ−サイナイ メディカル センター
シーダーズ−サイナイ メディカル センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シーダーズ−サイナイ メディカル センター, シーダーズ−サイナイ メディカル センター filed Critical シーダーズ−サイナイ メディカル センター
Publication of JP2019511243A publication Critical patent/JP2019511243A/ja
Publication of JP2019511243A5 publication Critical patent/JP2019511243A5/ja
Priority to JP2022036725A priority Critical patent/JP2022091801A/ja
Priority to JP2024025071A priority patent/JP2024063065A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8527—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic for producing animal models, e.g. for tests or diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8527—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic for producing animal models, e.g. for tests or diseases
    • C12N2015/8572—Animal models for proliferative diseases, e.g. comprising an oncogene
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Environmental Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2018557283A 2016-01-26 2016-12-30 インビボのデュアルリコンビナーゼ媒介性カセット交換（ｄＲＭＣＥ）のためのシステム及び方法ならびにその疾患モデル Pending JP2019511243A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022036725A JP2022091801A (ja) 2016-01-26 2022-03-10 インビボのデュアルリコンビナーゼ媒介性カセット交換（ｄＲＭＣＥ）のためのシステム及び方法ならびにその疾患モデル
JP2024025071A JP2024063065A (ja) 2016-01-26 2024-02-22 インビボのデュアルリコンビナーゼ媒介性カセット交換（ｄＲＭＣＥ）のためのシステム及び方法ならびにその疾患モデル

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662287197P 2016-01-26 2016-01-26
US62/287,197 2016-01-26
PCT/US2016/069442 WO2017131926A1 (en) 2016-01-26 2016-12-30 SYSTEMS AND METHODS FOR IN VIVO DUAL RECOMBINASE-MEDIATED CASSETTE EXCHANGE (dRMCE) AND DISEASE MODELS THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022036725A Division JP2022091801A (ja) 2016-01-26 2022-03-10 インビボのデュアルリコンビナーゼ媒介性カセット交換（ｄＲＭＣＥ）のためのシステム及び方法ならびにその疾患モデル

Publications (2)

Publication Number Publication Date
JP2019511243A true JP2019511243A (ja) 2019-04-25
JP2019511243A5 JP2019511243A5 (enExample) 2020-02-06

Family

ID=59398838

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018557283A Pending JP2019511243A (ja) 2016-01-26 2016-12-30 インビボのデュアルリコンビナーゼ媒介性カセット交換（ｄＲＭＣＥ）のためのシステム及び方法ならびにその疾患モデル
JP2022036725A Pending JP2022091801A (ja) 2016-01-26 2022-03-10 インビボのデュアルリコンビナーゼ媒介性カセット交換（ｄＲＭＣＥ）のためのシステム及び方法ならびにその疾患モデル
JP2024025071A Pending JP2024063065A (ja) 2016-01-26 2024-02-22 インビボのデュアルリコンビナーゼ媒介性カセット交換（ｄＲＭＣＥ）のためのシステム及び方法ならびにその疾患モデル

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022036725A Pending JP2022091801A (ja) 2016-01-26 2022-03-10 インビボのデュアルリコンビナーゼ媒介性カセット交換（ｄＲＭＣＥ）のためのシステム及び方法ならびにその疾患モデル
JP2024025071A Pending JP2024063065A (ja) 2016-01-26 2024-02-22 インビボのデュアルリコンビナーゼ媒介性カセット交換（ｄＲＭＣＥ）のためのシステム及び方法ならびにその疾患モデル

Country Status (8)

Country Link
US (2) US11466290B2 (enExample)
EP (1) EP3408396A4 (enExample)
JP (3) JP2019511243A (enExample)
KR (1) KR102811061B1 (enExample)
CN (1) CN108884472A (enExample)
AU (1) AU2016389495B2 (enExample)
CA (2) CA3303511A1 (enExample)
WO (1) WO2017131926A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022536934A (ja) * 2019-06-17 2022-08-22 シーダーズ－サイナイ メディカル センター ｉｎ ｖｉｖｏ二重リコンビナーゼ媒介カセット交換（ｄＲＭＣＥ）のためのシステム及び方法ならびにその疾患モデル
US11466290B2 (en) 2016-01-26 2022-10-11 Cedars-Sinai Medical Center Systems and methods for in vivo dual recombinase-mediated cassette exchange (dRMCE) and disease models thereof
US12258571B2 (en) 2018-03-16 2025-03-25 Cedars-Sinai Medical Center Methods and compositions for inducible expression of neurotrophic factors

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109321599B (zh) * 2018-09-27 2023-08-22 同济大学 人多能干细胞中的谱系示踪系统的构建与应用
CN109943564B (zh) * 2019-03-28 2022-03-15 上海市中医老年医学研究所 Amh基因定点敲入2A-Cre的杂合子小鼠模型构建方法及其应用
CA3140297A1 (en) * 2019-06-19 2020-12-24 Simon Auslaender Method for the generation of a protein expressing cell by targeted integration using cre mrna
CN119301241A (zh) 2022-06-06 2025-01-10 协和发酵生化株式会社 提高了3'-唾液酸乳糖的生产率的微生物和3'-唾液酸乳糖的制造方法
WO2024218715A1 (en) 2023-04-19 2024-10-24 Btl Healthcare Technologies A.S. Culture media based on protein hydrolysate and a process for preparing thereof
US12668774B2 (en) 2023-10-12 2026-06-30 Btl Healthcare Technologies A.S. Product, system and method of cell cultivation
WO2026050378A1 (en) * 2024-08-28 2026-03-05 Cedars-Sinai Medical Center Humanized genetically-engineered autochthonous brain tumors compatible with use in immunocompetent rodents

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011001247A2 (en) * 2009-06-29 2011-01-06 University Of Basel Methods and kits for high efficiency engineering of conditional mouse alleles
WO2014204724A1 (en) * 2013-06-17 2014-12-24 The Broad Institute Inc. Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7575924B2 (en) * 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
WO2003020743A1 (en) * 2001-09-05 2003-03-13 Regeneron Pharmaceuticals, Inc. Methods of expressing transgenes
WO2003090689A2 (en) 2002-04-25 2003-11-06 Wisconsin Alumni Research Foundation Neurodegenerative disorder treatment using gdnf secreting neural cells
GB2404382B (en) 2003-07-28 2008-01-30 Oxitec Ltd Pest control
CA2672203A1 (en) * 2006-12-21 2008-07-03 Genentech, Inc. Compositions and methods for the expression of nucleic acids
US8592211B2 (en) 2009-03-20 2013-11-26 The Rockefeller University Enhanced PiggyBac transposon and methods for transposon mutagenesis
US9528124B2 (en) * 2013-08-27 2016-12-27 Recombinetics, Inc. Efficient non-meiotic allele introgression
WO2013155222A2 (en) 2012-04-10 2013-10-17 The Regents Of The University Of California Brain-specific enhancers for cell-based therapy
WO2014127289A1 (en) 2013-02-15 2014-08-21 International Stem Cell Corporation Use of neural cells derived from human pluripotent stem cells for the treatment of neurodegenerative diseases
SG11201507829SA (en) 2013-03-21 2015-12-30 Univ Kyoto Pluripotent stem cell for neuronal differentiation induction
US9694036B2 (en) 2014-03-21 2017-07-04 Cellular Dynamics International, Inc. Production of midbrain dopaminergic neurons and methods for the use thereof
WO2015139093A1 (en) 2014-03-21 2015-09-24 The Sydney Children's Hospitals Network (Randwick And Westmead) (Incorporating The Royal Alexandra Hospital For Children) Stable gene transfer to proliferating cells
EP3122370A1 (en) 2014-03-28 2017-02-01 Buck Institute for Research on Aging Methods and compositions for modulating the immune system
EP3584312A1 (en) 2014-06-27 2019-12-25 Angiocrine Bioscience, Inc. Neural cells expressing adenovirus e4orf1, and methods of making and using the same
US12642852B1 (en) 2015-11-04 2026-06-02 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells
CA3303511A1 (en) 2016-01-26 2026-05-13 Cedars-Sinai Medical Center SYSTEMS AND METHODS FOR IN VIVO DUAL RECOMBINASE-MEDIATED CASSETTE EXCHANGE (dRMCE) AND DISEASE MODELS THEREOF
AU2019236288B2 (en) 2018-03-16 2025-06-05 Cedars-Sinai Medical Center Methods and compositions for inducible expression of neurotrophic factors
EP3983000A4 (en) 2019-06-17 2023-10-11 Cedars-Sinai Medical Center SYSTEMS AND METHODS OF DOUBLE RECOMBINASE-MEDIATED CASSETTE EXCHANGE (DRMCE) IN VIVO AND ASSOCIATED DISEASE MODELS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011001247A2 (en) * 2009-06-29 2011-01-06 University Of Basel Methods and kits for high efficiency engineering of conditional mouse alleles
WO2014204724A1 (en) * 2013-06-17 2014-12-24 The Broad Institute Inc. Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BIOTECHNIQUES (2013) VOL.55, NO.5, PP.233-242, JPN6020046795, ISSN: 0004637484 *
NATURE METHODS (2010) VOL.7, NO.11, PP.893-895, ONLINE METHODS, JPN6020046794, ISSN: 0004400970 *
PATHOGENETICS (2008) VOL.1, NO.3, PP.1-10, JPN6020046793, ISSN: 0004637485 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11466290B2 (en) 2016-01-26 2022-10-11 Cedars-Sinai Medical Center Systems and methods for in vivo dual recombinase-mediated cassette exchange (dRMCE) and disease models thereof
US12258571B2 (en) 2018-03-16 2025-03-25 Cedars-Sinai Medical Center Methods and compositions for inducible expression of neurotrophic factors
JP2022536934A (ja) * 2019-06-17 2022-08-22 シーダーズ－サイナイ メディカル センター ｉｎ ｖｉｖｏ二重リコンビナーゼ媒介カセット交換（ｄＲＭＣＥ）のためのシステム及び方法ならびにその疾患モデル

Also Published As

Publication number Publication date
KR20180101535A (ko) 2018-09-12
AU2016389495B2 (en) 2023-03-30
CA3303511A1 (en) 2026-05-13
US11466290B2 (en) 2022-10-11
EP3408396A4 (en) 2019-10-09
CN108884472A (zh) 2018-11-23
US20190390222A1 (en) 2019-12-26
AU2016389495A1 (en) 2018-08-16
WO2017131926A1 (en) 2017-08-03
US20230084201A1 (en) 2023-03-16
KR102811061B1 (ko) 2025-05-21
EP3408396A1 (en) 2018-12-05
CA3012042A1 (en) 2017-08-03
JP2022091801A (ja) 2022-06-21
JP2024063065A (ja) 2024-05-10

Similar Documents

Publication Publication Date Title
US20230084201A1 (en) SYSTEMS AND METHODS FOR IN VIVO DUAL RECOMBINASE-MEDIATED CASSETTE EXCHANGE (dRMCE) AND DISEASE MODELS THEREOF
US20160186208A1 (en) Methods of Mutating, Modifying or Modulating Nucleic Acid in a Cell or Nonhuman Mammal
US20220304286A1 (en) SYSTEMS AND METHODS FOR IN VIVO DUAL RECOMBINASE-MEDIATED CASSETTE EXCHANGE (dRMCE) AND DISEASE MODELS THEREOF
JP2019528068A (ja) Ｄｎａメチル化の編集方法
Bodea et al. LINE-1 retrotransposons contribute to mouse PV interneuron development
JP7641033B2 (ja) ヒト組織幹細胞及びその使用
Aparisi Rey et al. Gadd45α modulates aversive learning through post‐transcriptional regulation of memory‐related mRNAs
Zhang et al. Genome writing to dissect consequences of SVA retrotransposon disease X-Linked Dystonia Parkinsonism
Imle et al. Somatic gene delivery faithfully recapitulates a molecular spectrum of high-risk sarcomas
Tennant et al. Fluorescent in vivo editing reporter (FIVER): a novel multispectral reporter of in vivo genome editing
US11174495B2 (en) Reporter system for detecting and targeting activated cells
WO2012004346A1 (en) Genetically engineered stem cells, method of production and uses thereof
US10612022B2 (en) ETS factors regulate neural stem cell depletion and gliogenesis in Ras pathway glioma
Kim et al. Generating in vivo somatic mouse mosaics with locus-specific, stably-integrated transgenic elements
WO2025223110A1 (en) A method of generating a functional mch neurons
Grandela et al. STRAIGHT-IN: A platform for high-throughput targeting of large DNA payloads into human pluripotent stem cells
Thorsen The origin and properties of pro-oncogenic fields in the intestinal epithelium
WO2021242989A1 (en) Compositions and methods for inducing cas9 protein expression by use of autonomous pd-1 promoter activity
Karayol et al. Serotonin receptor 4 in mature excitatory hippocampal neurons modulates mood and anxiety
Distasio Novel Regulators of Neural Crest and Neural Progenitor Survival
Platt Applications of genome editing for disease modeling in mice
EP2455466A1 (en) Dna fragment and pharmaceutical composition
Li et al. The splicing regulator PTBP2 controls a program of embryonic splicing required for neuronal

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180829

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191219

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191219

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210225

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210308

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210601

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211111